ICCM Stock Overview A commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
IceCure Medical Ltd Competitors Price History & Performance
Summary of share price highs, lows and changes for IceCure Medical Historical stock prices Current Share Price US$1.12 52 Week High US$1.57 52 Week Low US$0.48 Beta 2.61 1 Month Change 57.26% 3 Month Change 75.58% 1 Year Change 21.08% 3 Year Change -60.56% 5 Year Change n/a Change since IPO 942.83%
Recent News & Updates
IceCure Medical Ltd. Announces Data from its ICE3 Trial of ProSense®? in Early-Stage Breast Cancer Dec 16
IceCure Medical Ltd. Announces Interim Results from the ICESECRET Study of Cryoablation for Patients with Small Renal Masses Dec 05
Consensus revenue estimates fall by 13% Dec 03
No longer forecast to breakeven Nov 27
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 26
IceCure Medical Ltd to Report Q3, 2024 Results on Nov 26, 2024 Nov 20 See more updates
IceCure Medical Ltd. Announces Data from its ICE3 Trial of ProSense®? in Early-Stage Breast Cancer Dec 16
IceCure Medical Ltd. Announces Interim Results from the ICESECRET Study of Cryoablation for Patients with Small Renal Masses Dec 05
Consensus revenue estimates fall by 13% Dec 03
No longer forecast to breakeven Nov 27
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 26
IceCure Medical Ltd to Report Q3, 2024 Results on Nov 26, 2024 Nov 20 IceCure Medical Ltd has filed a Follow-on Equity Offering. Oct 16
IceCure Medical Ltd. Announces Study Publishes in British Journal of Radiology Demonstrates IceCure's ProSense is Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of Lung, Bone, and Soft Tissues Sep 16
IceCure Medical Ltd. Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024 Sep 12
U.S. Patent and Trademark Office Grants Notice of Allowance for Additional Patent on IceCure Medical Ltd.'s Novel Cryogenic Pump Technology Aug 29
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 21
Forecast to breakeven in 2026 Aug 21
IceCure Medical Ltd Announces the Publication of an Independent Study of Patients Who Chose Cryoablation for the Treatment of Early Breast Cancer in Non-Surgical Patients Aug 15
IceCure Medical Ltd to Report Q2, 2024 Results on Aug 20, 2024 Aug 13
IceCure Medical Ltd. Announces Positive Data from the Largest Multi-Institutional Study of Its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials Aug 08
Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Invest In Growth? Jul 31
New minor risk - Share price stability Jul 23
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification Jul 23
IceCure Medical Ltd. Announces the Publication of an Independent Study Evaluating its Cryoablation System ProSense Jul 10
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes Jul 02
New minor risk - Shareholder dilution Jun 13
FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025 Jun 06
First quarter 2024 earnings: EPS in line with expectations, revenues disappoint May 30
IceCure Medical Ltd to Report Q1, 2024 Results on May 28, 2024 May 23
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound–Guided Cryoablation for Early–Stage Primary Breast Cancer: A Follow–Up Study in Japan," in the Journal Breast Cancer on April 27, 2024 May 08 IceCure Medical Ltd, Annual General Meeting, May 20, 2024
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Apr 03
Icecure Submits FDA Regulatory Filing for New Xsense™ Cryoablation System with Cryoprobes Apr 02
IceCure Medical Ltd to Report Fiscal Year 2023 Results on Apr 03, 2024 Mar 28
Price target increased by 14% to US$3.33 Mar 20
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study Mar 20
IceCure Medical Ltd. Announces Results from an Independent Study Mar 06
Icecure Medical Ltd. Announces New Data from A Preliminary, Independent Breast Cancer Study Feb 27
Icecure Medical Ltd. Announces U.S. Food and Drug Administration Has Responded Affirmatively to the Company’s Request for Supervisory Review Under 21 Cfr 10.75 Regarding the Fda’S Prior Denial of Icecure’S De Novo Classification Request for Treating Patients with Early-Stage, Low Risk Breast Cancer Jan 30
IceCure Medical Ltd has filed a Follow-on Equity Offering in the amount of $9.7 million. Jan 14 IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Forecast to breakeven in 2026 Dec 31
IceCure Medical Ltd. Announces the Publication of a Study Called "Cryoablation Allows the Ultimate De-Escalation of Surgical Therapy for Select Breast Cancer Patients Dec 13
IceCure Medical Ltd. Announces Release of a Study in a Series of Independent Studies of ProSense Nov 29
We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate Nov 29
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 17
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense in Early-Stage Breast Cancer Nov 17
IceCure Medical Ltd to Report Q3, 2023 Results on Nov 15, 2023 Nov 09
Icecure Medical Ltd. Announces Provides Update on Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's Prosense Cryoablation System Nov 08
New major risk - Revenue and earnings growth Sep 21
IceCure Medical Ltd. Receives FDA Response to De Novo Classification Request for Breast Cancer Sep 21
Price target decreased by 15% to US$3.41 Sep 20
Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil Sep 07
Icecure Medical's Prosense Cryoablation System Receives Regulatory Approval in Brazil Sep 06
Second quarter 2023 earnings: EPS misses analyst expectations Aug 16
IceCure Medical Ltd to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Deliver On Growth Plans? Aug 08
Health Canada Approves Icecure Medical's Minimally Invasive Prosense Cryoablation System Jul 25
New major risk - Financial position Jul 05
New major risk - Revenue and earnings growth Jun 29
IceCure Medical Ltd to Report Q1, 2023 Results on May 22, 2023 May 16
Insufficient new directors May 01
Full year 2022 earnings: EPS in line with expectations, revenues disappoint Mar 31
Price target decreased by 14% to US$3.96 Mar 22
IceCure Medical Ltd Receives Notice of Allowance from the U.S. Patent and Trademark Office for Its Patent Application Titled Cryogen Pump Jan 24
IceCure Medical Ltd Receives Notice of Patent Allowance in Japan for A Novel Cryogenic Pump for Its Next-Generation Cryoablation Systems Jan 19
IceCure Medical Ltd Announces Interim Results from the ICESECRET Study for the Treatment of Patients with Small Renal Masses Dec 21
IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors Dec 07
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Dec 05
IceCure Medical Ltd to Report Nine Months, 2022 Results on Dec 05, 2022 Nov 29
Price target decreased to US$4.58 Nov 16
IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures Nov 09
Price target decreased to US$4.58 Oct 25
IceCure Medical Ltd. Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery Oct 20
IceCure gains 19% on seeking FDA nod for cancer treatment Oct 19
IceCure Medical Ltd Submits Regulatory Filing in Vietnam for Approval of Prosense® Aug 30
Second quarter 2022 earnings released Aug 17
IceCure Medical Ltd to Report Q2, 2022 Results on Aug 15, 2022 Aug 10
IceCure Medical Ltd Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors Jul 26
IceCure files application for approval of ProSense in Canada for tumors Jul 25
IceCure Medical Ltd to Report Q1, 2022 Results on May 18, 2022 May 12
Price target decreased to US$7.58 Apr 27
Full year 2021 earnings released: US$0.35 loss per share (vs US$0.27 loss in FY 2020) Apr 02
Now 25% undervalued after recent price drop Feb 09
IceCure Medical Ltd, Annual General Meeting, Mar 03, 2022 Jan 28
IceCure Medical: Advancing Cryotherapy For Cancer Treatment Jan 25
Icecure Medical Ltd Medical Receives Notice of Intention to Grant A European Patent Covering Its Cryogenic Pump Dec 22
IceCure Medical's Interim Results of the ICE3 Clinical Trial for Early-Stage Breast Cancer Cryoablation featured at the 2021 Annual Meeting of the Radiological Society of North America Dec 03
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Nov 26
First half 2021 earnings released: US$0.16 loss per share (vs US$0.12 loss in 1H 2020) Sep 29
Icecure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the Ice3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer Sep 14
Icecure Medical Ordinary Shares Deleted from Other OTC Aug 27
IceCure Medical Ltd. Announces Positive Interim Results from ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting May 05
IceCure Signs Exclusive Distribution Agreement with Rise General Trading, LCC, Expanding Market Reach Across the Middle East Feb 18
IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand Jan 06
IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million Oct 06
IceCure Medical Ltd has completed a Follow-on Equity Offering in the amount of ILS 20.7 million. Aug 12 Shareholder Returns ICCM US Medical Equipment US Market 7D 4.7% -1.5% -2.4% 1Y 21.1% 10.0% 23.4%
See full shareholder returns
Return vs Market: ICCM underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is ICCM's price volatile compared to industry and market? ICCM volatility ICCM Average Weekly Movement 13.1% Medical Equipment Industry Average Movement 7.6% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ICCM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ICCM's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors.
Show more IceCure Medical Ltd Fundamentals Summary How do IceCure Medical's earnings and revenue compare to its market cap? ICCM fundamental statistics Market cap US$61.35m Earnings (TTM ) -US$13.83m Revenue (TTM ) US$3.67m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ICCM income statement (TTM ) Revenue US$3.67m Cost of Revenue US$2.07m Gross Profit US$1.60m Other Expenses US$15.44m Earnings -US$13.83m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.25 Gross Margin 43.67% Net Profit Margin -376.85% Debt/Equity Ratio 0%
How did ICCM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 03:08 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IceCure Medical Ltd is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Kemp Dolliver Brookline Capital Markets Yi Chen H.C. Wainwright & Co. Anthony Vendetti Maxim Group
Show 0 more analysts 
